Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Andreas Helke who wrote (599)	5/4/1998 10:39:00 PM
From: David Winkler	Read Replies (1) \| Respond to of 2135

I attended Folkman's talk last Nov. I will attempt to explain the mode of action. There are two molecules regulating vessel growth. One is very potent stimulator of growth but is very unstable and it breaks down rapidly. The second stops the growth of vessels, is long lived, circulates around the body. This is the molecule of interest. When a patient has a primary tumor, the potent but unstable stimulators causes vessels to grow locally, and the stable molecule prevents growth of vessels away from the tumor. As the tumor grows it sheds cells which become very small islands of cells that do not grow because of the circulating chemical. When surgeons remove the primary tumor, the source of the supressor is removed and the small clusters of cells grow out of control. This was the observation that led to all this. Essentially the entremed chemical will supress the small islands of cells from dividing and becoming metastatic tumors. In appropriate doses the primary tumor can be supressed/destroyed by the chemical too. The two compounds they are talking about somehow irradicate the tumor. If you are on the west coast, Date Line NBC just did a story on this. Probably did a better job than this.

To: Andreas Helke who wrote (599)	5/5/1998 12:04:00 AM
From: Bob Rudd	Respond to of 2135

In regard to whether anyone has rights to endostatin, here's a quote from a Times piece: " The patent on both the mouse and human forms of angiostatin belongs to Children's Hospital. It has licensed them to Entremed, a small biotechnology company in Rockville, Md., which has been a major supporter of Folkman's research since 1994. Entremed has in turn licensed Bristol Myers-Squibb, a large pharmaceuticals company, to produce and market angiostatin. The company also has an option, not yet exercised, to develop endostatin. "